肉毒杆菌毒素(ATGC Co)(Botulinum toxin(ATGC Co)) - 药物靶点：SNAP25_在研适应症：骨关节炎_专利_临床

概要

基本信息

药物类型

毒素

别名

ATGC 200、ATGC-200、ATGC200

靶点

SNAP25

作用方式

抑制剂

作用机制

SNAP25 抑制剂(突触相关蛋白25 抑制剂)

治疗领域

免疫系统疾病皮肤和肌肉骨骼疾病

在研适应症

骨关节炎

非在研适应症-

原研机构

ATGC Co. Ltd.

在研机构

ATGC Co. Ltd.

非在研机构-

权益机构-

最高研发阶段临床前

首次获批日期-

最高研发阶段(中国)-

特殊审评-

关联

100 项与肉毒杆菌毒素(ATGC Co) 相关的临床结果

登录后查看更多信息

100 项与肉毒杆菌毒素(ATGC Co) 相关的转化医学

登录后查看更多信息

100 项与肉毒杆菌毒素(ATGC Co) 相关的专利（医药）

登录后查看更多信息

2,513

项与肉毒杆菌毒素(ATGC Co) 相关的文献（医药）

2025-12-31·ANNALS OF MEDICINE

Efficacy of isolated periocular botulinum toxin A injections versus periocular and adjunctive lower facial injections in hemifacial spasm: a randomized, controlled, noninferiority, crossover trial

Article

作者: Chirapapaisan, Niphon ; Rueangcharin, Phakinee ; Mukdar, Yanee ; Joradoln, Manassawee ; Rattanathamsakul, Natthapon ; Eiamsamarng, Akarawit ; Chuenkongkaew, Wanicha

PURPOSE:

To evaluate the necessity of botulinum toxin A (BoNT-A) administration in the lower face of patients with hemifacial spasm (HFS).

METHODS:

A randomized controlled non-inferiority crossover trial was conducted with 46 HFS patients (non-inferiority margin = 1). Patients were randomized (1:1) to receive either isolated periocular BoNT-A injections followed by conventional injections (periocular and lower face area) or the reverse sequence, with a 16-week washout. Primary outcomes were visual analog scale (VAS) for periocular and lower face regions at 4 weeks post injection. Secondary outcomes included the Hemifacial Spasm Grading Scale (HSGS), Samsung Medical Center grading system (SMC), HFS questionnaire (HFS-30), and adverse events. Trial registration: TCTR20220916002.

RESULTS:

Data from 43 patients were analyzed. Isolated periocular injections demonstrated non-inferiority to conventional injections. Periocular VAS was 0.488 ± 0.140 (isolated injections) and 0.279 ± 0.085 (conventional) , mean difference 0.209 (95% CI: 0.064, 0.354, p<0.01). Lower face VAS was 0.878 ± 0.167 and 0.582 ± 0.113, mean difference 0.295 (95% CI: 0.039, 0.552, p<0.01). No significant differences were noted in HSGS, SMC, or HFS-30 scores. Minor adverse events were observed in both techniques, while mouth drooping occured only with conventional injections.

CONCLUSION:

Isolated periocular injections resulted in slightly poorer symptom relief but did not exceed the non-inferiority margin, providing comparable efficacy to conventional injections in controlling HFS while using a lower total toxin dose and minimizing adverse effects.

2025-12-01·JPRAS open

Age-related changes in platysma insertion height and the clinical role of high-resolution ultrasound in the elderly

Article

作者: Kildal, Villiam Vejbrink ; Tzou, Chieh-Han John ; Weninger, Wolfgang J ; Meng, Stefan ; Reissig, Lukas ; Pruidze, Paata ; Rodriguez-Lorenzo, Andrés ; Reilly, Frank O F

Background:

There is no consensus on the exact insertion height of the platysma muscle, and the influence of aging on its cranial position remains unexplored. Additionally, clinicians currently rely solely on clinical examination to assess the muscle-a limitation that may contribute to complications when treating platysma synkinesis with botulinum toxin injections. This study aimed to determine the cranial insertion height of the platysma in an elderly cohort, explore how aging affects its cranial position, and validate high-resolution ultrasound as a non-invasive tool for visualizing and assessing the muscle in the neck and face.

Methods:

Thirty-eight hemifaces were studied in body donors of advanced age (mean: 83.5±8.7). Using high-resolution 22 MHz ultrasound, the platysma muscle was assessed in the neck, and the cranial insertion height was established within a coordinate system and verified through anatomical dissection. The effect of age on insertion height was analyzed using linear mixed-effects models.

Results:

The cranial platysma insertion height was found 2.9 ± 1.0 cm above the mandibular angle. Increasing age was associated with a decrease in insertion height by 0.54 mm per year (p<0.05). Ultrasound successfully identified the platysma in the neck in 34 of the 38 hemifaces but underestimated the cranial insertion height by 0.84 cm (mean).

Conclusions:

The platysma muscle often extended into the midface, but increasing age was associated with a reduction in its discernible insertion height. High-resolution 22 MHz ultrasonography of the platysma can reliably assess the platysma and guide treatment in the neck in elderly patients but underestimates the cranial insertion height in the face.

2025-12-01·Techniques in Coloproctology

Efficacy and safety of botulinum toxin injection in the management of chronic symptomatic anal fissure: a systematic review and meta-analysis of randomized controlled trials

Review

作者: Abdelaziz, H ; Gruber, M ; Thippeswamy, K Maradi ; Abdel-Dayem, M

BACKGROUND:

Anal fissure is one of the most painful anal conditions. Various management options are available, including topical nitrites, calcium channel blockers, botulinum toxin injection, and lateral internal sphincterotomy. This study aimed to assess the efficacy and safety of botulinum toxin A (BT) injection for the management of symptomatic chronic anal fissures by conducting a systematic review of the literature and meta-analysis of published randomized controlled trials (RCTs).

METHODS:

A systematic search was conducted using the Embase and Medline search platforms. The search identified 264 papers published from January 1974 to December 2023, 35 of which were RCTs. Meta-analysis was performed on the collected data with a random effects model using Freeman-Tukey arcsine-transformed proportions. A p value less than 0.05 was considered to indicate statistical significance. The I² test was used to assess heterogeneity.

RESULTS:

A total of 1532 patients were included. After data were pooled, 1117 patients out of 1532 (72.7%) demonstrated healing of the fissure after the first injection of BT (P < 0.001, I² = 86.6%). Subgroup analysis was performed on the basis of the follow-up period in months. Nine studies reported that a second BT injection was needed for patients who did not respond after the initial injection. Twenty-nine out of 38 patients (78.5%) responded to the second injection (p < 0.001, I² = 50.6%). Complications were observed in 88 out of 1532 patients (4.02%) (p < 0.001, I² = 60.2%).

CONCLUSION:

BT injection is a safe treatment approach for chronic symptomatic anal fissures, typically associated with only minor, temporary complications. Evidence also supports the use of repeat injections for managing recurrent or persistent symptoms.

100 项与肉毒杆菌毒素(ATGC Co) 相关的药物交易

登录后查看更多信息